Search Share Prices
4D Pharma cancer treatment shown to stimulate immune system response
Pharmaceutical company 4D Pharma reported on Wednesday that its lead oncology candidate has demonstrated immune-stimulatory characteristics in pre-clinical models.
The MRx0518 is a strain of live bacteria extracted and purified from healthy human faecal samples developed to stimulate pathways that are associated with the body's response to cancer and has seen a successful development programme at 4D Pharma's GMP production plant.
Duncan Peyton, chief executive of 4D Pharma, said: "This is a key step in the development of a true microbiome derived pharmaceutical product for the treatment of cancer. Understanding the mode of action of MRx0518, through the identification of a specific gene product and its interaction with a high profile human oncology target, gives greater insight into its potential applications and benefits to cancer patients."
The company said that plans are at an advanced stage to open UK and US based clinical studies in the near future.
Data concerning the MRx0518 bacteria was presented at the Microbiome Research and Development and Business Collaboration Forum in Rotterdam on Wednesday by Peyton.
As of 1106 GMT, 4D Pharma's shares were up 3.08% at 134.00p.